We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed at $96.34 in the latest trading session, marking a +1.94% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.53%. Meanwhile, the Dow experienced a drop of 0.09%, and the technology-dominated Nasdaq saw a decrease of 1%.
Coming into today, shares of the pharmaceutical had gained 3.46% in the past month. In that same time, the Medical sector gained 0.09%, while the S&P 500 gained 2.06%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 10, 2026. The company's upcoming EPS is projected at $1.09, signifying a 3.81% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.76 billion, up 5.81% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.59 per share and a revenue of $58.73 billion, indicating changes of +11.68% and 0%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.03% higher within the past month. Astrazeneca is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 18.33. This signifies a discount in comparison to the average Forward P/E of 20.82 for its industry.
Investors should also note that AZN has a PEG ratio of 1.56 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.49.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 96, this industry ranks in the top 40% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
Astrazeneca (AZN - Free Report) closed at $96.34 in the latest trading session, marking a +1.94% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.53%. Meanwhile, the Dow experienced a drop of 0.09%, and the technology-dominated Nasdaq saw a decrease of 1%.
Coming into today, shares of the pharmaceutical had gained 3.46% in the past month. In that same time, the Medical sector gained 0.09%, while the S&P 500 gained 2.06%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 10, 2026. The company's upcoming EPS is projected at $1.09, signifying a 3.81% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.76 billion, up 5.81% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.59 per share and a revenue of $58.73 billion, indicating changes of +11.68% and 0%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.03% higher within the past month. Astrazeneca is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 18.33. This signifies a discount in comparison to the average Forward P/E of 20.82 for its industry.
Investors should also note that AZN has a PEG ratio of 1.56 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.49.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 96, this industry ranks in the top 40% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.